drugset

drugset / Trial / NCT02489214

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

NCT02489214 ↗

Phase 1/2 Terminated 13 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NaSingle-groupOpen-labelTreatment

Summary

This open-label, one-center, noncomparative, two-stage phase 1B trial assessed the donafenib in advanced gastric cancer.

Timeline

Start: 2016-05-16
Primary completion: 2019-06-13
Completion: 2019-06-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donafenib	Small molecule	200 mg	—

Indications